Monte Rosa Therapeutics (GLUE) Stock Price

Monte Rosa Therapeutics Price

NASDAQ·CLOSED
16.22USD+0.84 (+5.29 %)
Market closed

For Monte Rosa Therapeutics, the net margin of -31.2% is up versus -96.1% a few years ago. The consensus 12-month price target for Monte Rosa Therapeutics is 31.62 USD, about 95.0% above where the stock trades today. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus. Monte Rosa Therapeutics's share price has gained 235.7% over the last twelve months. The stock trades about 287% above its 52-week low.

Monte Rosa Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Monte Rosa Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Monte Rosa Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Monte Rosa Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Monte Rosa Therapeutics Stock Price History
DateMonte Rosa Therapeutics Price
8/4/202616.22 USD
8/3/202615.38 USD
7/31/202616.52 USD
7/30/202622.68 USD
7/29/202621.81 USD
7/27/202622.81 USD
7/23/202623.03 USD
7/22/202623.79 USD
7/21/202623.63 USD
7/20/202623.48 USD
7/17/202624.56 USD
7/16/202623.16 USD
7/15/202623.41 USD
7/14/202623.46 USD
7/13/202621.57 USD
7/10/202623.04 USD
7/9/202624.52 USD
7/8/202624.18 USD
7/7/202624.40 USD
7/6/202623.92 USD
7/2/202624.21 USD
7/1/202624.02 USD
6/30/202624.20 USD
6/29/202622.98 USD
6/26/202622.29 USD
6/25/202621.66 USD
6/24/202620.85 USD
6/23/202620.71 USD
6/22/202618.42 USD
6/18/202618.15 USD
6/17/202618.96 USD
6/16/202617.84 USD
6/15/202618.42 USD
6/12/202618.02 USD
6/11/202616.91 USD
6/10/202616.95 USD
6/9/202616.61 USD
6/8/202617.00 USD
6/5/202616.72 USD
6/4/202617.60 USD
6/3/202617.80 USD
6/2/202618.55 USD
6/1/202619.73 USD
5/29/202619.48 USD
5/28/202619.10 USD
5/27/202619.48 USD
5/26/202618.91 USD
5/22/202619.35 USD
5/21/202618.65 USD
5/20/202618.88 USD
5/19/202617.58 USD
5/18/202618.01 USD
5/15/202618.15 USD
5/14/202618.68 USD
5/13/202618.96 USD
5/12/202619.11 USD
5/11/202620.26 USD
5/8/202619.39 USD
5/7/202619.81 USD
5/6/202620.39 USD
5/5/202619.35 USD
5/4/202619.57 USD
5/1/202618.80 USD
4/30/202619.15 USD
4/29/202618.72 USD
4/28/202619.01 USD
4/27/202619.29 USD
4/24/202619.79 USD
4/23/202620.17 USD
4/22/202620.98 USD
4/21/202620.89 USD
4/20/202619.81 USD
4/17/202619.78 USD
4/16/202618.70 USD
4/15/202618.23 USD
4/14/202617.50 USD
4/13/202617.55 USD
4/10/202617.48 USD
4/9/202618.05 USD
4/8/202617.12 USD
4/7/202617.12 USD
4/6/202616.93 USD
4/2/202617.09 USD
4/1/202617.17 USD
3/31/202616.45 USD
3/30/202615.53 USD
3/27/202615.38 USD
3/26/202615.67 USD
3/25/202615.71 USD
3/24/202614.72 USD
3/23/202615.03 USD
3/20/202615.63 USD
3/19/202616.06 USD
3/18/202615.76 USD
3/17/202616.03 USD
3/16/202616.35 USD
3/13/202616.02 USD
3/12/202616.04 USD
3/11/202617.06 USD
3/10/202617.28 USD
3/9/202617.66 USD
3/6/202617.80 USD
3/5/202617.95 USD
3/4/202618.61 USD
3/3/202617.96 USD
3/2/202618.50 USD
2/27/202617.75 USD
2/26/202618.50 USD
2/25/202618.09 USD
2/24/202619.21 USD
2/23/202619.51 USD
2/20/202618.98 USD
2/19/202619.16 USD
2/18/202618.28 USD
2/17/202618.36 USD
2/13/202617.92 USD
2/12/202618.50 USD
2/11/202618.96 USD
2/10/202619.57 USD
2/9/202619.59 USD
2/6/202619.55 USD
2/5/202618.90 USD
2/4/202619.53 USD
2/3/202620.93 USD
2/2/202620.88 USD
1/30/202620.52 USD
1/29/202621.36 USD
1/28/202621.13 USD
1/27/202623.10 USD
1/26/202622.39 USD
1/23/202622.84 USD
1/22/202623.02 USD
1/21/202624.23 USD
1/20/202624.44 USD
1/16/202623.71 USD
1/15/202624.08 USD
1/14/202624.06 USD
1/13/202623.99 USD
1/12/202623.72 USD
1/9/202624.28 USD
1/8/202625.31 USD
1/7/202623.28 USD
1/6/202616.01 USD
1/5/202614.40 USD
1/2/202615.31 USD
12/31/202515.68 USD
12/30/202515.97 USD
12/29/202516.12 USD
12/26/202517.29 USD
12/24/202517.64 USD
12/23/202516.48 USD
12/22/202516.19 USD
12/19/202515.54 USD
12/18/202515.83 USD
12/17/202516.75 USD
12/16/202518.66 USD
12/15/202516.45 USD
12/12/202516.31 USD
12/11/202516.56 USD
12/10/202517.23 USD
12/9/202516.99 USD
12/8/202517.85 USD
12/5/202517.41 USD
12/4/202517.26 USD
12/3/202516.86 USD
12/2/202515.41 USD
12/1/202515.78 USD
11/28/202516.17 USD
11/26/202515.99 USD
11/25/202516.02 USD
11/24/202515.76 USD
11/21/202514.22 USD
11/20/202513.52 USD
11/19/202514.14 USD
11/18/202513.78 USD
11/17/202513.61 USD
11/14/202514.36 USD
11/13/202514.32 USD
11/12/202514.16 USD
11/11/202514.32 USD
11/10/202514.06 USD
11/7/202512.31 USD
11/6/202513.01 USD
11/5/202512.31 USD
11/4/202512.00 USD
11/3/202512.07 USD
10/31/202512.85 USD
10/30/202513.01 USD
10/29/202512.50 USD
10/28/202512.43 USD
10/27/202512.32 USD
10/24/202511.14 USD
10/23/202510.38 USD
10/22/20259.35 USD
10/21/20259.59 USD
10/20/20259.87 USD
10/17/202510.05 USD
10/16/202510.31 USD
10/15/202511.11 USD
10/14/202510.61 USD
10/13/202510.40 USD
10/10/202510.04 USD
10/9/20258.46 USD
10/8/20257.71 USD
10/7/20257.38 USD
10/6/20257.66 USD
10/3/20257.74 USD
10/2/20257.63 USD
10/1/20257.50 USD
9/30/20257.41 USD
9/29/20257.31 USD
9/26/20257.49 USD
9/25/20256.55 USD
9/24/20256.62 USD
9/23/20256.33 USD
9/22/20256.53 USD
9/19/20256.33 USD
9/18/20256.93 USD
9/17/20256.36 USD
9/16/20256.47 USD
9/15/20256.93 USD
9/12/20254.81 USD
9/11/20254.89 USD
9/10/20254.80 USD
9/9/20254.83 USD
9/8/20254.80 USD
9/5/20254.94 USD
9/4/20254.91 USD
9/3/20255.00 USD
9/2/20254.92 USD
8/29/20254.80 USD
8/28/20254.83 USD
8/27/20254.67 USD
8/26/20254.67 USD
8/25/20254.59 USD
8/22/20254.82 USD
8/21/20254.50 USD
8/20/20254.43 USD
8/19/20254.40 USD
8/18/20254.56 USD
8/15/20254.58 USD
8/14/20254.35 USD
8/13/20254.44 USD
8/12/20254.45 USD
8/11/20254.19 USD
8/8/20254.38 USD
8/7/20254.23 USD
8/6/20254.36 USD
8/5/20254.83 USD
Access this data via the Eulerpool API
Get Free API Key

Monte Rosa Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-143.31 M USD
-135.35 M USD
Jan 1, 2024
75.62 M USD
-81.11 M USD
-72.70 M USD
Jan 1, 2025
123.67 M USD
-54.21 M USD
-38.63 M USD
Jan 1, 2026 (e)
44.46 M USD
15.57 M USD
-120.78 M USD
Jan 1, 2027 (e)
58.21 M USD
20.39 M USD
-133.89 M USD
Jan 1, 2028 (e)
22.25 M USD
7.79 M USD
-167.28 M USD
Jan 1, 2029 (e)
115.14 M USD
40.33 M USD
-153.86 M USD
Jan 1, 2030 (e)
169.09 M USD
59.23 M USD
-117.69 M USD

Monte Rosa Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 8:52 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20192020202120222023202420252026e2027e2028e2029e2030e
–––––75.00123.0044.0058.0022.00115.00169.00
––––––64.00-64.2331.82-62.07422.7346.96
–––––89.3393.5093.5093.5093.5093.5093.50
115.00115.00-2.00-8.00-6.0067.00115.0041.1454.2320.57107.52158.01
-7.00-28.00-72.00-112.00-143.00-81.00-54.0015.0020.007.0040.0059.00
–––––-108.00-43.9034.0934.4831.8234.7834.91
-8.00-35.00-73.00-108.00-135.00-72.00-38.00-120.00-133.00-167.00-153.00-117.00
–337.50108.5747.9525.00-46.67-47.22215.7910.8325.56-8.38-23.53
65.5421.7445.9948.8956.9361.4465.5465.5465.5465.5465.5465.54
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Monte Rosa Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Monte Rosa Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Monte Rosa Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Monte Rosa Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Monte Rosa Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Monte Rosa Therapeutics stock margins

The Monte Rosa Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Monte Rosa Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Monte Rosa Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
93.24 %
- %
- %
Jan 1, 2022
93.24 %
- %
- %
Jan 1, 2023
93.24 %
- %
- %
Jan 1, 2024
89.26 %
-107.26 %
-96.14 %
Jan 1, 2025
93.24 %
-43.83 %
-31.23 %
Jan 1, 2026 (e)
93.24 %
35.03 %
-271.69 %
Jan 1, 2027 (e)
93.24 %
35.03 %
-230.02 %
Jan 1, 2028 (e)
93.24 %
35.03 %
-751.81 %

Monte Rosa Therapeutics Stock Revenue, EBIT, Earnings per Share

The Monte Rosa Therapeutics earnings per share therefore indicates how much revenue Monte Rosa Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 USD
-1.58 USD
-1.61 USD
Jan 1, 2022
0.00 USD
-2.30 USD
-2.22 USD
Jan 1, 2023
0.00 USD
-2.52 USD
-2.38 USD
Jan 1, 2024
1.23 USD
-1.32 USD
-1.18 USD
Jan 1, 2025
1.89 USD
-0.83 USD
-0.59 USD
Jan 1, 2026 (e)
0.61 USD
0.24 USD
-1.66 USD
Jan 1, 2027 (e)
0.80 USD
0.31 USD
-1.84 USD
Jan 1, 2028 (e)
0.31 USD
0.12 USD
-2.29 USD

Monte Rosa Therapeutics business model & stock analysis

Monte Rosa Therapeutics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Monte Rosa Therapeutics Employees
Details
Date
Monte Rosa Therapeutics Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Monte Rosa Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Monte Rosa Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Monte Rosa Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Monte Rosa Therapeutics shares outstanding

The number of shares of Monte Rosa Therapeutics was 65.54 M in 2025. This indicates how many shares Monte Rosa Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
45.99 M Stocks
Jan 1, 2022
48.89 M Stocks
Jan 1, 2023
56.93 M Stocks
Jan 1, 2024
61.44 M Stocks
Jan 1, 2025
65.54 M Stocks
Jan 1, 2026 (e)
65.54 M Stocks
Jan 1, 2027 (e)
65.54 M Stocks
Jan 1, 2028 (e)
65.54 M Stocks

Current Monte Rosa Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
3.33 %
Buy
93.33 % (14)
Hold
6.67 % (1)
Sell
0.00 % (0)
12M Price Target
31.62
Last Price
15.48
Currency
USD
12M Return Potential
104.33 %
LTM Return
0 %

Monte Rosa Therapeutics Analyst Rating Actions

DateFirmActionRatingReliability
6/30/2026
Guggenheim
Guggenheim
MaintainedBuy30
5/11/2026
JP Morgan
JP Morgan
MaintainedOverweight80
3/18/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
3/18/2026
Guggenheim
Guggenheim
MaintainedBuy30
1/14/2026
Piper Sandler
Piper Sandler
MaintainedOverweight51
1/8/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
1/8/2026
Guggenheim
Guggenheim
MaintainedBuy30
12/16/2025
Wells Fargo
Wells Fargo
UpgradeEqual WeightOverweight56
11/7/2025
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
3/21/2025
Wells Fargo
Wells Fargo
MaintainedEqual Weight56

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Monte Rosa Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/6/2026-0.39USD-5.63 MUSD-2026 Q2
5/7/2026-0.39USD-11.10 MUSD-2026 Q1
3/12/2026-0.36USD-15.82 MUSD-2025 Q4
8/7/2025-0.39USD-11.02 MUSD-2025 Q2
11/22/2022-0.61USD-0.00USD-2022 Q3

EESG©

Eulerpool ESG Scorecard© for the Monte Rosa Therapeutics stock

59/100
62
Environment
73
Social
41
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Monte Rosa Therapeutics shareholder structure

% Name
10.54896%
NEA MANAGEMENT COMPANY, LLC
NEA MANAGEMENT COMPANY, LLC
9.21584%
PRICE T ROWE ASSOCIATES INC /MD/
PRICE T ROWE ASSOCIATES INC /MD/
7.73133%
BLACKROCK, INC.
BLACKROCK, INC.
6.33866%
TCG CROSSOVER MANAGEMENT, LLC
TCG CROSSOVER MANAGEMENT, LLC
6.11751%
BVF INC/IL
BVF INC/IL
5.95959%
BAKER BROS. ADVISORS LP
BAKER BROS. ADVISORS LP
...

Monte Rosa Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
70.7%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
17.30%
Walker
Walker
SEC ↗
17.30%
Peter W. Sonsini
Peter W. Sonsini
SEC ↗
17.30%
Liza Landsman
Liza Landsman
SEC ↗
17.30%
Joshua Makower
Joshua Makower
SEC ↗
17.30%
H. Makhzoumi
H. Makhzoumi
SEC ↗
17.30%
D. Sandell
D. Sandell
SEC ↗
17.30%
Baskett
Baskett
SEC ↗
15.30%
GP-GP,
GP-GP,
SEC ↗
13.87%
Abigail P. Johnson
Abigail P. Johnson
SEC ↗
9.99%
Baker Bros. Advisors LP
Baker Bros. Advisors LP
SEC ↗

Monte Rosa Therapeutics Executives and Management Board

13 members · avg. age 53 · 31 % women

MW

Dr. Markus Warmuth (54)

President, Chief Executive Officer, Director · since 2020

2.44 M USD

Management

PN

Dr. Philip Nickson (45)

Chief Business and Legal Officer

1.29 M USD
FJ

Dr. Filip Janku (50)

Chief Medical Officer

1.26 M USD
JC

Ms. Jennifer Champoux (53)

Chief Operating Officer

–
ST

Dr. Sharon Townson (50)

Chief Scientific Officer

–

Board of Directors

EH

Dr. Eric Hughes (55)

Independent Director

281,355.00 USD
AS

Dr. Andrew Schiff (58)

Non-Executive Independent Chairman of the Board

164,831.00 USD
CS

Ms. Christine Siu (48)

Independent Director

124,016.00 USD
KB

Dr. Kimberly Blackwell (56)

Independent Director

123,391.00 USD
AB

Dr. Ali Behbahani (48)

Independent Director

117,766.00 USD
AM

Dr. Anthony Manning (63)

Independent Director

112,498.00 USD

Frequently asked questions about Monte Rosa Therapeutics

Analysts currently set an average price target of 29.87 USD for the Monte Rosa Therapeutics stock (median: 31.62 USD), implying +93.0 % versus the latest price. The consensus is based on 15 analyst ratings.

Monte Rosa Therapeutics Analyst Price Targets 2026

15 analysts currently rate the Monte Rosa Therapeutics stock: 14 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Monte Rosa Therapeutics to generate revenue of 44.46 M USD and earnings per share of -1.84 USD.

Monte Rosa Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the Monte Rosa Therapeutics share trades at 14.07 EUR (16.22 USD).

The Monte Rosa Therapeutics share (GLUE) is listed on 1 stock exchanges, including: NASDAQ (GLUE).

No history available for Monte Rosa Therapeutics.

The expected revenue of Monte Rosa Therapeutics is 44.46 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Monte Rosa Therapeutics is -120.78 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Monte Rosa Therapeutics is currently -8.80. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Monte Rosa Therapeutics stock.

The price-to-sales ratio (P/S) of Monte Rosa Therapeutics is currently 23.91. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Monte Rosa Therapeutics stock.

The Eulerpool Quality Score for Monte Rosa Therapeutics is 3/10.

The ISIN of Monte Rosa Therapeutics is US61225M1027. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Monte Rosa Therapeutics is GLUE. The ticker symbol is used to trade Monte Rosa Therapeutics shares on the stock exchange.

Monte Rosa Therapeutics paid dividends every year for the past 0 years.

Monte Rosa Therapeutics is assigned to the 'Health' sector.

The dividends of Monte Rosa Therapeutics are distributed in USD.

All fundamentals and in-depth analysis of Monte Rosa Therapeutics

Our stock analysis for Monte Rosa Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Monte Rosa Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics Revenue→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics Net Income→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics P/E→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics P/S→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics EBIT→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics Dividend→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics Directors Dealings→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics Stocks→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics Market capitalization→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics Debt→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics Liabilities→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics Equity→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics AAQS→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics Employees→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics ROE→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics ROA→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics ROCE→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics News→
Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics Analyst Price Targets→

Health Stocks

MoonLake ImmunotherapeuticsMonsenso A/SMorepen LaboratoriesMonopar TherapeuticsMotus GI HoldingsMono PharmacareMouwasat Medical Services Company SJSCMonash IVF GroupMPH Health CareMolina HealthcareMRTMolecureAll Stocks A–Z →